Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux in HNSCC (Window of Opportunity)
NCT03769311Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Wisconsin–Madison. Primary endpoints: Change in Tumor Size at 42 days and Objective Tumor Response Rate - AXL Expression at 42 days. Started Apr 2019; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03769311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769311.